Discover a study on PARP inhibitors in prostate cancer, revealing survival benefits for patients with BRCA1/2 alterations.

People diagnosed with advanced breast cancer in 2025 can expect to live for an extra six or seven months, compared to the ...

Potential first-in-class, and industry-leading DNA polymerase Theta (Polθ) inhibitor, ART6043 demonstrated an attractive tolerability profile, ...

Olaparib is the only PARP inhibitor that significantly improves overall survival in PSROC, distinguishing it from other PARP inhibitors. All four PARP inhibitors enhance progression-free survival, ...

Niraparib approved for all-comers whose tumors responded to chemotherapy Platinum response serves as a clinical biomarker indicating potential DNA repair deficiency. The FDA restricted ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the best stocks to buy with over 50% upside potential. Canaccord ...

Ways to accelerate the local implementation and adoption of the homologous recombination deficiency (HRD) testing in India. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...

Personalized Medicine. 2015;12(2):139-154. Compared to AstraZeneca, the other pharmaceutical companies have fewer Phase III trials running for their compounds. However, the approaches within these ...

HONOLULU — A new analysis of the phase 3 NOVA trial strengthens earlier findings that niraparib (Zejula, Tesaro) provides meaningful clinical benefit for patients with platinum-sensitive, recurrent ...